Perrigo Company plc
PRGO
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $2.1B
$14.92
▲ +4.55%
P/E
-6.40
Mkt Cap
$2.1B
52-Wk Range
$9.23–$22.90
52-Week Range
$9.23 - $22.90
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 33.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Turning profitable
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+28.5% over 3m
Quality
Stable
Solid business
Dividend
High yield
7.77% yield
Smart-money signal
Who's buying PRGO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $0.50 vs $0.31 consensus (+61.3% surprise). Revenue of $1.0B vs $1.0B expected (+0.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+61.3%
Revenue trend · last 2Q
—
-3%
Q1 26
Q2 26
$969.2M
$1.0B
Margins · last 2Q
Gross
30.7%
Operating
-37.5%
Profit
6.4%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How PRGO stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.